Ever Supreme Bio Technology to Expand into Cross-Border Cell Therapy CDMO Collaboration, Aiming to Complete Three Phase I Clinical Trials This Year

Ever Supreme Bio Technology presented at an earnings conference hosted by the Taipei Exchange on the 7th. Chairperson Judy Liu stated that the company’s CDMO orders are growing steadily, with visibility now extending into the first quarter of 2026. Looking ahead, the company plans to expand into international cell therapy contract manufacturing collaborations. As for its pipeline, three therapies are expected to complete Phase I clinical trials this year: the CAR-T therapy CAR001 for solid tumors, and the allogeneic umbilical cord mesenchymal stem cell therapy UMSC01 for acute ischemic stroke and multiple sclerosis (MS).